论文部分内容阅读
目的:评价红花黄色素与缬沙坦联用治疗早期糖尿病肾病患者的临床疗效。方法:选取2011年12月—2013年12月收治的2型糖尿病患者72例,将其分为对照组患者和观察组患者,每组36例;对照组患者均给予单用缬沙坦治疗,观察组患者均给予红花黄色素和缬沙坦联用治疗,比较两组患者患者治疗后的临床疗效。结果:两组患者治疗后空腹血糖值、餐后2 h血糖值和Hb A1c、TC、TG值均高于治疗前(P<0.05);观察组患者治疗后的疗效优于对照组(P<0.05);观察组患者肾功能指标改善程度优于对照组(P<0.05)。结论:缬沙坦与红花黄色素联用对2型糖尿病伴肾病患者早期的临床疗效较好。
Objective: To evaluate the clinical efficacy of safflor yellow combined with valsartan in the treatment of patients with early diabetic nephropathy. Methods: Seventy-two patients with type 2 diabetes who were admitted from December 2011 to December 2013 were divided into control group and observation group with 36 cases in each group. Patients in the control group were treated with valsartan alone, Patients in the observation group were treated with safflor yellow combined with valsartan. The clinical efficacy of the two groups of patients after treatment was compared. Results: The fasting blood glucose, postprandial blood glucose, Hb A1c, TC and TG were higher in both groups after treatment than those before treatment (P <0.05). The therapeutic effect of the observation group was better than that of the control group (P < 0.05). The improvement of renal function in observation group was better than that in control group (P <0.05). Conclusion: The combination of valsartan and safflower yellow pigment in type 2 diabetic patients with nephropathy early clinical efficacy is better.